Fri, Aug 29, 2014, 2:54 AM EDT - U.S. Markets open in 6 hrs 36 mins


% | $
Quotes you view appear here for quick access.

Cytori Therapeutics, Inc. Message Board

john.gerondis 3 posts  |  Last Activity: Jul 8, 2014 11:54 AM Member since: Nov 25, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    OMER to $12 Get Out Now!

    by hold_still23 Jul 8, 2014 10:32 AM
    john.gerondis john.gerondis Jul 8, 2014 11:54 AM Flag

    Get IN now before they announce European approval of Omidria. Get IN now before they announce a distribution aggreement with European partner/distributor ............... but most of all get in now because $21 is more than feasible when they start selling this must have product.

    What you should be teeling people is buy more as it approaches $12 ............ but that's too much like good advice.

  • john.gerondis john.gerondis Jul 8, 2014 11:44 AM Flag

    A lot more to the latest patent than in the announcement. Some additional claims of this application are as follows:

    11. The method of claim 1, further comprising culturing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells prior to mixing said cell population that comprises adipose-derived stem cells with said second portion of unprocessed adipose tissue comprising intact, non disaggregated tissue fragments from said subject.

    12. The method of claim 11 wherein said culturing step comprises exposing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells to culture conditions that promote differentiation towards an endothelial phenotype.

    13. The method of claim 11, wherein said culturing step is performed on a scaffold.

    14. The method of claim 13, wherein said scaffold is resorbable in vivo.

    It seems to me that they have been working on a lot of things we know nothing about. It is also interesting to note that this patent application was filed in August 2012. This was on the basis of work done prior to that date ........ makes you wonder what has been developef/refined since then ????????

    Culturing, scaffolds, exposure to promote differentiation ..........

  • Reply to

    Zacks using robo ghost writers....

    by scubamoe Jun 12, 2014 3:01 PM
    john.gerondis john.gerondis Jun 12, 2014 3:44 PM Flag

    Totally transparent article designed to help the shorts. It has no doubt been followed up with increased shorting. The secret is to not panic. Selling genuine long positions is what they want as it gives them the opportunity to nickle and dime us to death (or so they hope).

    We have broken old highs and are in a fundamentally excellent position.

    Eye surgeons/ophthalmologists are not going to risk not using this drug. An individuals eyesight is of paramount value to one's quality of life. If a patient loses his eyesight for USD50 - USD300 (take your pick) because the surgeon was too cheap to conduct the operation under optimum conditions......... ie. using Omidria....... then I suggest he/she does not skimp on malpractice insurance.

    Smart shorts who are still long will be trying to get out ........... don't let them. This drug has the potential to make Omeros independent of the curse of constant dilution. No new shares is every shorts nightmare, and is usually a statistical outlier event ............... usually.......

1.38+0.01(+0.73%)Aug 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.